Roche/Genentech announce the locations, including 20 sites in the U.S. and 6 in Canada, for their phase 3 study - called GENERATION HD1 - to test efficacy of the huntingtin-lowering therapy RG6042.
This study is open and currently recruiting! This will be a 2-year study in people with early diagnosed HD, involving monthly spinal injections to deliver RG6042 or a placebo, as well as clinical tests and scans to understand the effect of the drug on HD symptoms. Around 660 people age 25-65 will be recruited at approximately 90 sites across the world.
Read the full press release.